Abstract:Tumor drug resistance (TDR) invariably leads to the failure of chemotherapy. In addition, current treatment strategies for TDR are not satisfactory due to limitations in terms of safety and feasibility. The aim of the present study was to determine whether low-intensity low-frequency ultrasound (LILFU) could improve the effect of chemotherapy and reverse TDR in gemcitabine-resistant ASPC-1 (ASPC-1/GEM) cells. The investigation focused on the association between LILFU effectiveness and the adenosine triphosphate-binding cassette (ABC) transporters and the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/nuclear factor (NF)-kappa B signaling pathway. A Cell Counting Kit-8 assay was used to determine the appropriate acoustic intensity, half-maximal inhibitory concentration of gemcitabine (GEM) and the viability of ASPC-1/GEM cells. ASPC-1/GEM cells were divided into control, GEM, LILFU and GEM+LILFU groups. Cell proliferation was evaluated through colony formation assays, whereas cell apoptosis was detected using flow cytometry. Western blotting was used to explore the expression levels of ABC transporters and PI3K/AKT/NF-kappa B signaling pathway-associated proteins. Xenograft models in mice were established to identify the enhancing effect of GEM+LILFUin vivo. Immunohistochemistry was used to detect the expression levels of Ki-67 in tumor tissues. The acoustic parameter of 0.2 W/cm(2)and a GEM concentration of 6.63 mg/ml were used in subsequent experiments. Following treatment with GEM+LILFU, the cell viability and proliferation ability were decreased, whereas the apoptotic rate was increased compared with the GEM group. The expression levels of ABC transporters,PI3K-P110 alpha andNF-kappa Bwere decreased in the GEM+LILFU group. Notably, LILFU increased the effectiveness of GEM in inhibiting tumor growth, and reduced the expression levels of Ki-67 in the xenograft mouse model. LILFU improved the chemosensitivity of ASPC-1/GEM cells via inhibition of cell viability and proliferation, and promoted cell apoptosis in the GEM+LILFU group. In conclusion, LILFU may downregulate the expression levels of ABC transporters by inhibiting the PI3K-p110 alpha/AKT/NF-kappa B signaling pathway, thereby reversing resistance in pancreatic cancer.

TNP-470 Combined with Gemcitabine Inhibits the Expression of Vascular Endothelial Cell Growth Factor and Its Receptors in Human Pulmonary Adenocarcinoma Cells and Umbilical Vein Endothelium Cells

Inhibition of Expression of Vascular Endothelial Growth Factor and Its Receptors in Pulmonary Adenocarcinoma Cell by TNP-470 in Combination with Gemcitabine

[RAD001 Reverses Radio-Resistance and Exerts Synergistic Tumor Inhibition with 5-Fluorouracil].

Effect of transcatheter arterial chemoembolization on angiogenesis and expression of vascular endothelial growth factor in cervical squamous cell carcinoma

Low‑intensity Low‑frequency Ultrasound Enhances the Chemosensitivity of Gemcitabine‑resistant ASPC‑1 Cells Via PI3K/AKT/NF‑κB Pathway‑mediated ABC Transporters.

Modulating Tumour Vascular Normalisation Using Triptolide-Loaded NGR-functionalized Liposomes for Enhanced Cancer Radiotherapy

[Cancer therapy targeting tumor-induced neovascularization]

Antitumor Effect of FP3 in Combination with Cetuximab on Patient-Derived Tumor Tissue Xenograft Models of Primary Colon Carcinoma and Related Lymphatic and Hepatic Metastases

Effect of gemcitabine-loaded albumin nanoparticles on the micro-angiogenesis of pancreatic cancer

N1-guanyl-1, 7-diaminoheptane enhances the sensitivity of pancreatic ductal adenocarcinoma cells to gemcitabine via the inhibition of eukaryotic translation initiation factor 5A2.

(3E,5E)-3,5-Bis(pyridin-3-methylene)-tetrahydrothiopyran-4-one enhances the inhibitory effect of gemcitabine on pancreatic cancer cells

Effect of Gemcitabine on Proliferation, Apoptosis and Polo-Like Kinase-1 Expression of Pancreatic Cancer Cell Line AsPC-1

Inhibitory Effect of the Angiogenesis Inhibitor TNP-470 on Tumor Growth and Metastasis in Nude Mice Bearing Human Hepatocellular Carcinoma

FP3: a Novel VEGF Blocker with Antiangiogenic Effects in Vitro and Antitumour Effects in Vivo

Antitumor Effect of FP3 in a Patient-Derived Tumor Tissue Xenograft Model of Gastric Carcinoma Through an Antiangiogenic Mechanism.

The Effects of Nimotuzumab Alone and in Combination with Chemotherapy on Pulmonary Adenocarcinoma

The killing effect of rmhTNF-α combined with gemcitabine on human lune adenocarcinoma cells A549

O-chloroacetylcarbamoyl fumagillol combined with 5-fluorouracil in suppression of the growth of gastric cancer

The Combination Effect of Gemcitabine with Mitomycin on Human Lung Cancer A549 Cell Line in Vitro

Effect of 406 nm-gemcitabine-loaded albumin nanoparticles on in vitro human pancreatic cancer cells CFPAC-1

Visualization Research on ENT1/NIS Dual-Function Gene Therapy to Reverse Drug Resistance Mediated by MUC1 in GEM-resistant Pancreatic Cancer